Coya Therapeutics, Inc. Announces Peer-Reviewed Publication of Phase 2a Clinical Trial Data for COYA 101 in Amyotrophic Lateral Sclerosis (ALS)
Phase 2a publication entitled “Combined Regulatory T-Lymphocyte and IL-2 Treatment is Safe, Tolerable, and Biologically Active for One Year in Persons with Amyotrophic Lateral Sclerosis” has been published in peer-reviewed journal Neurology, Neuroimmunology & Neuroinflammation COYA 101 was well tolerated and increased Treg suppressive function The majority (6 out of 8) of patients either slowed […]
Coya Therapeutics Announces Peer-Reviewed Publication of its First- in-Class Regulatory T cell derived Exosomes and Their Therapeutic Potential in Neurodegeneration and Inflammation-Related Diseases
Regulatory T cell (Treg)-derived exosome data have been published in the peer-reviewed journal Frontiers of Immunology Characterization of Treg-derived exosomes show Treg cells-conserved functional moieties and demonstrate potent immunomodulatory function on pro-inflammatory myeloid cells and T cell proliferation, while also showing anti-inflammatory function in multiple in vivo pre-clinical disease models Treg-derived exosomes maintain Treg cell […]
Coya Therapeutics Secures Option Agreement for Exclusive Worldwide Rights to Exosome Engineering Technology from Carnegie Mellon University
Proprietary technology generates Exosome Polymer Hybrids (EPHs) which allow for efficient and versatile method of customizing cargoes of Treg-derived exosomes using oligonucleotide tethers Delivering EPHs to sites of inflammation or epitopes that drive specific diseases, while delivering payloads, enables the next generation of selectively targeted and potent Treg-derived exosomes No genetic modification is required, thereby […]
